Search studies
60 studies found
In vivo study
7bf49da4-91c2-11ed-901b-acde48001122
LIH-PREDI-COVID
e6f84ce3-04f3-11ec-a683-d0577bab103e
PREDI-COVID participants` samples and data for COVIRNA
LUCENT-1 (NCT 03518086)
ELU-4-58F581-1
An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
LuxPark
ELU-4-F67092-1
The cohort includes people with Parkinson’s disease, atypical parkinsonism, and healthy controls, who have their state of health regularly monitored by specialists over many years. The participants donate samples of body fluids such as blood or urine. They also take part in clinical examinations that analyze movement sequences and test their attention, memory, vision, speech, and sense of smell.
MIBIPA
ELU-4-E34987-1
Non-invasive microbiome-derived multi-omic biomarkers for the early-stage detection and stratification of Parkinson's disease
ND4BB Translocation
dc9bfdfe-147a-11eb-b51f-8c8590c45a21
OncoTrack
dc9c42f0-147a-11eb-b51f-8c8590c45a21
OncoTrack attempts to address the core problems of drug-based cancer therapies: the low response rate of patients to their therapies, as well as its inevitable consequence, the low approval rates of oncology drugs. Only about 10% of cancer drug candidates entering clinical development are granted marketing authorization. Our program is based on two seminal developments: significant progress in our ability to analyze the molecular characteristics of individual tumors and patients (predominantl...
OncoTrack study
ELU-4-24D114-1
OncoTrack attempts to address the core problems of drug-based cancer therapies: the low response rate of patients to their therapies, as well as its inevitable consequence, the low approval rates of oncology drugs. Only about 10% of cancer drug candidates entering clinical development are granted marketing authorization. Our program is based on two seminal developments: significant progress in our ability to analyze the molecular characteristics of individual tumors and patients (predominantl...